穿孔素1(PRF1)活性蛋白
Active Perforin 1 (PRF1)
FLH2; HPLH2; P1; PFP; Pore Forming Protein; Cytolysin; Lymphocyte pore-forming protein
- 编号APB317Hu02
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 缓冲液成份20mM Tris, 150mM NaCl, pH8.0, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 80%
- 等电点7.8
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 1800 ¥ 4500 ¥ 9000 ¥ 27000 ¥ 67500
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
Figure. SDS-PAGE
-
通过ISO 9001、ISO 13485质量体系认证
活性实验
Perforin 1 (PRF1) is a pore forming cytolytic protein found in the granules of cytotoxic T lymphocytes (CTLs) and NK cells. Upon degranulation, perforin binds to the target cell's plasma membrane, and oligomerises in a Ca2 dependent manner to form pores on the target cell. The pore formed allows for the passive diffusion of a family of pro-apoptotic proteases, known as the granzymes, into the target cell. The activity of recombinant PRF1 was measured by lysis of erythrocytes using a hemolysis assay. A general procedure is as fllows: two-fold dilute the recombinant human PRF1 with 0.9% NaCl, add 50μl a serial dilution of PRF1, 10μl 0.1M CaCl2 to each well, then add 50μl 0.25% rabbit erythrocyte (RaE) to each well and mixed gently. Add 50μl 0.9% NaCl to reaplace PRF1 in control wells. The plate is incubated for 20 hours at 37 ℃, 5% CO2. The results are shown in Figure 2. It was obvious that the minimal effective concentration of PRF1 is 2.5μg/ml.
用法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPB317Hu02 | 穿孔素1(PRF1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APB317Hu01 | 穿孔素1(PRF1)活性蛋白 | Cell culture; Activity Assays. |
| RPB317Hu01 | 穿孔素1(PRF1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APB317Hu02 | 穿孔素1(PRF1)活性蛋白 | Cell culture; Activity Assays. |
| PAB317Hu01 | 穿孔素1(PRF1)多克隆抗体 | WB; IHC; ICC; IP. |
| LAB317Hu81 | 穿孔素1(PRF1)多克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. |
| LAB317Hu71 | 穿孔素1(PRF1)多克隆抗体(生物素标记) | WB; IHC; ICC. |
| MAB317Hu22 | 穿孔素1(PRF1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAB317Hu21 | 穿孔素1(PRF1)单克隆抗体 | WB; IHC; ICC; IP. |
| SEB317Hu | 穿孔素1(PRF1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB317Hu | 穿孔素1(PRF1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Diagnostic Microbiology and Infectious Disease | Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfection [Pubmed:26915636] |
| FASEB JOURNAL | The immunoregulatory effects of CD8 T-cell–derived perforin on diet-induced nonalcoholic steatohepatitis [Pubmed: 30951375] |
| Theranostics | A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors [Pubmed: 31695790] |
| Mol Immunol | CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection [Pubmed: 33223223] |
| INVESTIGATIONAL NEW DRUGS | Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors [Pubmed: 32772342] |
| Am J Transl Res | Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma [34377237] |
| Nat Biomed Eng | Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy [34873307] |
| J Exp Med | Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion [Pubmed:35061012] |